All In Biotech

Drug Trial Radar · NCT02974010

Sequential Therapy for the Treatment of Severe Bipolar Depression.

Sequential Therapy (NRX-100 Followed by NRX-101) for the Treatment of Acute Suicidal Ideation and Behavior in Bipolar Depression: the STABIL-B Study

Last checked: Nov 19, 2026Latest source record: May 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

22

Actual

Start

Jan 15, 2018

Primary completion

Aug 31, 2018

Study completion Nov 20, 2019

Sponsor

Lead sponsor
NeuroRx, Inc.Industry
Sponsor type
Industry
Collaborators
Massachusetts General Hospital; Target Health Inc.
First posted
Nov 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or 5) or Behavior (ASIB) in following initial stabilization. Patients with Severe Bipolar Depression and ASIB will be recruited in both inpatient and outpatient settings and, following informed consent, will be given an intravenous infusion of ketamine 0.5mg/kg over 40 minutes. Those who exhibit a satisfactory clinical response to ketamine will be randomly allocated to NRX-101 or to lurasidone alone (the comparator group). This study is conducted as a feasibility study for a pivotal phase 2b/3 clinical trial and the primary outcomes for this phase 2 study were blood levels of NRX-101, in order to confirm pharmaco-kinetics with remission from depression, as measured by BISS-derived MADRS and relapse as secondary outcomes.

Conditions

  • Bipolar Depression
  • Suicidal Ideas
  • Suicidal Ideation
  • Suicide, Attempted

Interventions

  • NRX-101 Oral CapsuleDrug

    Prospective Randomized Factorial Design Study as per arm/group descriptions

  • Lurasidone Oral CapsuleDrug

    Prospective Randomized Factorial Design Study as per arm/group descriptions

  • Ketamine Intravenous InfusionDrug

    Randomized administration of Ketamine or Placebo in a 3 to 1 ratio

  • Saline Solution Intravenous InfusionDrug

    Randomized administration of Ketamine or Placebo in a 3 to 1 ratio

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BDM Score (BISS-derived MADRS) Change From Baseline at Day 42Time frame: Day 42

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site, Birmingham

    Birmingham, Alabama

  • Research Site, Fort Lauderdale

    Fort Lauderdale, Florida

  • Research Site, Charlotte

    Charlotte, North Carolina

  • Research Site, Houston

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.